Tina’s Wish is announcing the launch of a new program, the Acceleration to Clinic (“A2C”) Grant. The A2C Grant is designed to provide integrated grant funding and expert advisory resources to investigator teams whose biomarkers have achieved a defined level of clinical readiness as measured by the National Cancer Institute’s Early Detection Research Network (EDRN) five-phase biomarker development framework. These advisory resources strengthen translational decision-making, de-risk development pathways, and better position projects for successful clinical advancement and external funding. The A2C grant awards $1M in total costs over 2 years. The application cycle is now open.
Key Dates
- LOI application deadline: September 9, 2026 *
- Full application invitation: October 26, 2026
- Full proposal submission deadline: December 15, 2026
- Finalist presentations: March 29, 2027 (tentative)
- Notification of award: April 5, 2027
- Start of Year 1 funding: July 1, 2027
A2C LOI Guidelines – Click Here
A2C Full Application – By Invitation Only
* Submission Instructions
Details to follow soon! Tina’s Wish is migrating to a new portal for grant application submissions. In the meantime, we encourage researchers to prepare materials in anticipation of our portal launch. Once the grant application portal is live, Tina’s Wish will send an email announcement and update the Submission Instructions here.
Click Here for all other Tina’s Wish grant opportunities.